Loading…
Rein Therapeutics Inc. is projected to rise to $1.05 by 2027, a +9% move from its current price of $0.96. RNTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.926 | $0.961 | $0.9974 | +0.11% |
| Jul 13 | $0.9128 | $0.9621 | $1.01 | +0.22% |
| Jul 14 | $0.9031 | $0.9631 | $1.03 | +0.33% |
| Jul 15 | $0.8951 | $0.9642 | $1.04 | +0.44% |
| Jul 16 | $0.8883 | $0.9652 | $1.05 | +0.54% |
| Jul 17 | $0.8822 | $0.9663 | $1.06 | +0.65% |
| Jul 18 | $0.8767 | $0.9673 | $1.07 | +0.76% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8767 | $0.9673 | $1.07 | +0.76% |
| Week 2 | $0.8482 | $0.9747 | $1.12 | +1.53% |
| Week 3 | $0.8284 | $0.9821 | $1.16 | +2.31% |
| Week 4 | $0.813 | $0.9896 | $1.20 | +3.09% |
| Week 5 | $0.8004 | $0.9972 | $1.24 | +3.87% |
| Week 6 | $0.7897 | $1.00 | $1.28 | +4.67% |
| Week 7 | $0.7806 | $1.01 | $1.31 | +5.47% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rein Therapeutics Inc. is a biopharmaceutical company focused on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.
The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis.
The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Rein Therapeutics Inc. trades under the symbol RNTX. The current price is $0.96 and the market capitalization is $82.12M, with a rank of 4287. The stock sits in a small-cap healthcare space with ongoing clinical efforts in IPF and LPE indications as described above.
Near term, the price context shows a 30-day trading range from $0.7514 to $1.23, with a 50-day simple moving average of $1.03 and a 200-day simple moving average of $1.26. These levels provide near-term support around $0.865 and resistance near $1.11 as the market digests clinical progress and other news.
Longer-term, the forecast landscape envisions upside from the current level, with average prices progressing toward higher levels through 2030 and beyond. The forecast highlights a path toward multi-year appreciation, with notable increases in the 2040 and 2050 horizons, underscored by rising average prices and substantial ROIs by those years.
A major floor 22.9% below — a decisive break under it would weaken the trend.
The nearest floor, 9.9% below — buyers have tended to step in here.
The nearest ceiling, 15.6% above — a clean break opens room to run.
A major ceiling 95.8% above — clearing it would confirm fresh momentum.
Key RNTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9976 | Sell | $0.9906 | Sell |
| MA 10 | $1.00 | Sell | $0.9897 | Sell |
| MA 20 | $0.969 | Sell | $0.9915 | Sell |
| MA 50 | $1.03 | Sell | $1.06 | Sell |
| MA 100 | $1.20 | Sell | $1.15 | Sell |
| MA 200 | $1.26 | Sell | $1.29 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.38 | Neutral |
| Stoch RSI (14) | 64.93 | Neutral |
| CCI (20) | 20.37 | Neutral |
| Williams %R (14) | -44.12 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 1.14 | Buy |
| Bollinger %B (20,2) | 0.56 | Neutral |
| Stochastic %K (14) | 55.88 | Neutral |
| TRIX (15) | -0.33 | Sell |
| Awesome (5,34) | 0.01 | Buy |
| Ultimate (7,14,28) | 42.95 | Neutral |
| Momentum (10) | 0.05 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 0.98 | Sell |
| ADX (14) | 12.83 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is neutral, with RSI(14) at 50. The stock trades around the 50-day moving average of $1.03 and below the 200-day moving average of $1.26, indicating a balanced intermediate view.
The 30-day range is $0.7514 to $1.23, providing a defined near-term band. Support stands at $0.865 while resistance sits at $1.11, defining a modestly bullish breakout path if near-term momentum shifts.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.865 | $0.96 | $1.38 | 0% | Neutral | |
| $0.8041 | $1.05 | $1.45 | +9% | Neutral | |
| $1.04 | $1.41 | $2.06 | +47% | Bullish | |
| $1.19 | $1.66 | $2.51 | +73% | Bullish | |
| $1.04 | $1.50 | $2.35 | +57% | Bullish | |
| $1.07 | $1.58 | $2.53 | +65% | Bullish | |
| $1.07 | $1.63 | $2.67 | +69% | Bullish | |
| $1.04 | $1.62 | $2.71 | +68% | Bullish | |
| $1.28 | $2.03 | $3.48 | +112% | Bullish | |
| $1.41 | $2.30 | $4.01 | +140% | Bullish | |
| $1.55 | $2.79 | $5.25 | +191% | Bullish | |
| $2.48 | $5.40 | $11.31 | +462% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.865 | $0.96 | $1.19 | +0.00% |
| August 2026 | $0.8833 | $1.05 | $1.30 | +9.68% |
| September 2026 | $0.8806 | $1.06 | $1.32 | +0.66% |
| October 2026 | $0.844 | $1.02 | $1.30 | -3.36% |
| November 2026 | $0.8534 | $1.04 | $1.33 | +1.82% |
| December 2026 | $0.866 | $1.07 | $1.38 | +2.15% |
Click any year to see its month-by-month RNTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RNTX could reach as high as $1.38, with a base case around $0.96 and support toward $0.865 — roughly 0% from $0.96. A consolidation phase looks the most probable path here.
Expect RNTX to range from $0.8041 to $1.45 through 2027. The $1.05 average target implies a +9% move from current prices. That is up +9% on the projected 2026 average. Price action looks broadly range-bound.
The RNTX price prediction for 2028 points to an average of $1.41 (low $1.04, high $2.06) — a potential gain of +47% on today's $0.96. Buyers look set to stay in control over this stretch.
In 2029, RNTX is projected to trade between $1.19 and $2.51, averaging $1.66 — a potential gain of +73% from today's $0.96. That is up +18% on the projected 2028 average. Momentum favours further upside here.
Rein Therapeutics Inc.'s 2030 outlook centres on $1.50, within a $1.04 to $2.35 range. That is -10% versus the projected 2029 average. That marks a +57% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, RNTX could reach as high as $2.53, with a base case around $1.58 and support toward $1.07 — roughly +65% from $0.96. Momentum favours further upside here.
Expect RNTX to range from $1.07 to $2.67 through 2032. The $1.63 average target implies a +69% move from current prices. That is up +3% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The RNTX price prediction for 2033 points to an average of $1.62 (low $1.04, high $2.71) — a potential gain of +68% on today's $0.96. Momentum favours further upside here.
In 2034, RNTX is projected to trade between $1.28 and $3.48, averaging $2.03 — a potential gain of +112% from today's $0.96. That is up +26% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Rein Therapeutics Inc.'s 2035 outlook centres on $2.30, within a $1.41 to $4.01 range. That is up +13% on the projected 2034 average. That marks a +140% change versus current levels. Momentum favours further upside here.
By 2040, RNTX could reach as high as $5.25, with a base case around $2.79 and support toward $1.55 — roughly +191% from $0.96. Buyers look set to stay in control over this stretch.
Expect RNTX to range from $2.48 to $11.31 through 2050. The $5.40 average target implies a +462% move from current prices. That is up +93% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RNTX today (≈ 1,041.666667 RNTX) could be worth
$5,620.05
+$4,620.05 (+462%) by 2050 · US Dollar
Based on the average projected RNTX price of $5.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNTXwould be worth at today's price.
$1,000 invested in RNTX on Jul 10, 2025 (≈ 675.675667 RNTX) would be worth
$648.65
-$351.35 (-35.1%) today · 0.65× · US Dollar
Based on a RNTX entry price of $1.48 vs. today's $0.96.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.992 | $967.74 | -3.2% |
| 1 month ago | $0.92 | $1,043.48 | +4.3% |
| 3 months ago | $1.49 | $644.3 | -35.6% |
| 6 months ago | $1.15 | $834.78 | -16.5% |
| 1 year ago | $1.48 | $648.65 | -35.1% |
| All time (5.0y) ago | $23 | $41.74 | -95.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNTX forecast.
Our base-case forecast reaches $1.90 around 2034.
Implied market cap at $1.90: $162.52M
The multi-year forecast shows a trajectory of steady to accelerating upside. For 2026 the average price is $0.96 with a min of $0.865 and a max of $1.38 and a 0% ROI; by 2027 the average is $1.05 (min $0.8041, max $1.45) with an 8.9 ROI and NEUTRAL sentiment. The outlook strengthens into 2028 with an average of $1.41 and a max of $2.06, a 46.8 ROI, and a BULLISH stance, followed by 2029 with average $1.66, min $1.19, max $2.51 and a 73 ROI.
In 2030 the forecast shows average $1.50, min $1.04, max $2.35 with a 56.6 ROI and a BULLISH sentiment.
The bullish trend continues into 2031-2033 with averages around $1.58–$1.62 and ROIs in the 64.7–68.2 range, then 2034–2035 push higher to $2.03–$2.30 with 111.8–139.7 ROIs. By 2040, the average price is $2.79 with a max of $5.25 and a 190.9 ROI, and by 2050 the average reaches $5.40 with a max of $11.31 and a 462 ROI, all with a bullish sentiment.
Drivers include the ongoing development of LTI-03 in Phase 2 for IPF and the broader pipeline, including LTI-01 (completed Phase 1b/2a in LPE) and preclinical programs targeting cystic fibrosis and caveolin-1 peptide strategies. Risks include the inherent uncertainties of early-stage clinical programs and regulatory outcomes, which could influence the realized path of the forecast.
Tap a question to reveal the answer.
2030 forecast: min $1.04, avg $1.50, max $2.35; ROI 56.6; sentiment BULLISH.
Forecasts show a path from neutral near term to bullish longer term, with 2028 avg $1.41, 2029 $1.66, and 2030 $1.50 along with ROIs of 46.8% (2028), 73% (2029), and 56.6% (2030); by 2040 ROI is 190.9 and by 2050 ROI is 462 with a 5.40 avg in 2050.
Yes. The 2050 forecast shows an average price of $5.40 and a maximum of $11.31.
Current price is $0.96. The 30-day range is $0.7514 to $1.23.
2027 min $0.8041, avg $1.05, max $1.45; ROI 8.9; sentiment NEUTRAL.
Rein Therapeutics Inc. Community Discussion
0Share your Rein Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.